FDA Celgene Faces Off-Label Promotion Lawsuit Over Successful Cancer Drugs… Thomas Sullivan Aug 14, 2014 0 Since 2006, Celgene Corporation has earned $20.9 billion from the sales of two of its drugs—Thalomid and Revlimid. The drugs are…
Medical Legal Antitrust Lawsuit Against Celgene Over Thalomid and Revlimid Focuses on… Thomas Sullivan Aug 14, 2014 0 Celgene's successful cancer drugs Thalomid and Revlimid are at the center of an antitrust action. On April 3rd, Mylan…
